L J Seman

Author PubWeight™ 8.84^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study.	JAMA	1996	3.68
2	Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.	Diabetes Obes Metab	2013	1.37
3	Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease.	Am J Cardiol	2001	1.22
4	Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a).	Biochem Cell Biol	1986	1.05
5	The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters.	Atherosclerosis	2000	0.84
6	The linkage with apolipoprotein (a) in lipoprotein (a) modifies the immunochemical and functional properties of apolipoprotein B.	Biochemistry	1988	0.81
7	Lipoprotein(a) and coronary heart disease.	Chem Phys Lipids	1994	0.75
8	Ascorbic acid supplementation does not lower plasma lipoprotein(a) concentrations.	Atherosclerosis	2000	0.75
9	Lipid lowering and weight reduction by home-delivered dietary modification in coronary heart disease patients taking statins.	Am J Cardiol	2001	0.75
10	The laboratory's role in identifying lipid and lipoprotein risk factors for CHD.	MLO Med Lab Obs	1999	0.75